ESCO2: A Potential Drug Target and Biomarker for Establishment of Sister Chromatid Cohesion

Target Name: ESCO2

NCBI ID: G157570

ESCO2: A Potential Drug Target and Biomarker for Establishment of Sister Chromatid Cohesion

Introduction

Chromatin is the complex of DNA, RNA, and proteins that make up the chromosomes. Chromatin organization and dynamics are critical for the proper functioning of the cell, including DNA replication, gene expression, and cell division. One of the key processes that regulate chromatin organization and dynamics is the establishment of sister chromatid cohesion (SCC), which involves the formation of a stable complex between homologous chromosomes on the same sister chromatid. SCC is a critical process for maintaining genetic stability, as it ensures that the genetic information from each parent is effectively passed on to the offspring.

N-acetyltransferase 2 (NAT2) is an enzyme that plays a crucial role in the establishment of SCC. NAT2 is involved in the acetylation of specific lysine residues on the protein components, including histone histone-1 (H1), histone-2 ( H2), and histone-3 (H3), which are histone subunits that make up the nucleosome. Histone acetylation is a post-translational modification that modifies the physical and functional interactions between chromatin proteins, including the ability of chromatin to bind to various transcription factors.

ESCO2: A Potential Drug Target

The establishment of SCC is a critical process for the development and progression of many diseases, including cancer. In cancer, SCC is often disrupted, leading to changes in chromosomal organization and gene expression that contribute to the development of a malignant phenotype. Therefore, targeting the regulation of SCC by NAT2 is a promising strategy for the development of new cancer therapies.

ESCO2, or N-acetyltransferase 2, is a potential drug target for cancer because of its involvement in the regulation of SCC. By inhibiting NAT2 activity, researchers have found that they can disrupt SCC formation and induce apoptosis (1) in cancer cells. Additionally , ESCO2 has also been shown to be a biomarker for cancer, as its levels have been found to be elevated in various types of cancer.

ESCO2 has also been shown to play a role in the regulation of cell cycle progression in various cell types, including cancer cells. In addition, ESCO2 has also been shown to be involved in the regulation of angiogenesis, a process that is critical for the development of new blood vessels that feed into tumors.

ESCO2: A Potential Biomarker

ESCO2 has also been shown to be a potential biomarker for cancer, as its levels have been found to be elevated in various types of cancer. This suggests that ESCO2 may be a useful biomarker for the diagnosis and monitoring of cancer. Additionally, since ESCO2 is involved in the regulation of SCC, researchers have used it to study the effects of various therapeutic interventions on SCC formation and its role in cancer progression.

Conclusion

In conclusion, ESCO2 is a promising drug target and biomarker for cancer because of its involvement in the regulation of SCC. By inhibiting NAT2 activity, researchers have found that they can disrupt SCC formation and induce apoptosis in cancer cells. Additionally, ESCO2 has also been shown to be a biomarker for cancer and has been used to study the effects of various therapeutic interventions on SCC formation and its role in cancer progression. Further research is needed to fully understand the role of ESCO2 in the regulation of SCC and its potential as a drug target and biomarker for cancer.

Protein Name: Establishment Of Sister Chromatid Cohesion N-acetyltransferase 2

Functions: Acetyltransferase required for the establishment of sister chromatid cohesion (PubMed:15821733, PubMed:15958495). Couples the processes of cohesion and DNA replication to ensure that only sister chromatids become paired together. In contrast to the structural cohesins, the deposition and establishment factors are required only during the S phase. Acetylates the cohesin component SMC3 (PubMed:21111234)

More Common Targets